In this paper, we have investigated the use of GSK1070916, a reversible and ATP competitive inhibitor of Aurora B and Aurora C kinases (AURKB/C), to purge ovarian cortex tissue fragments contaminated with foci of chronic myeloid leukaemia (CML) or acute myeloid leukaemia (AML) from cell lines and of primary cancer cells from patients with AML. This evidence concerns the gene AURKB and chronic myelogenous leukemia, BCR-ABL1 positive.